Princeton Alpha Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Princeton Alpha Management’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-1,808	Closed	-$219K	–	442
2017 Q1	$219K	Buy	+1,808	New	+$233K	0.07%	451
2016 Q4	–	Sell	-12,394	Closed	-$1.52M	–	929
2016 Q3	$1.52M	Sell	12,394 -15,371	-55%	-$1.98M	0.28%	80
2016 Q2	$3.24M	Buy	+27,765	New	+$3.94M	0.58%	16
2015 Q2	–	Sell	-5,827	Closed	-$1.01M	–	947
2015 Q1	$1.01M	Buy	+5,827	New	+$1.05M	0.22%	135
2014 Q3	–	Sell	-6,106	Closed	-$954K	–	877
2014 Q2	$954K	Buy	6,106 +2,446	+67%	+$386K	0.2%	156
2014 Q1	$557K	Buy	+3,660	New	+$582K	0.17%	166

Other funds holding ALXN

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Princeton Alpha Management's ALXN Position: Q2 2017 in Review

Princeton Alpha Management sold out of Alexion Pharmaceuticals (ALXN) in Q2 2017, closing a stake of 1,808 shares — an estimated $219K sold.

Princeton Alpha Management first reported a position in ALXN in Q1 2014 and held it in 6 quarters. The position peaked at $3.24M in Q2 2016. 559 funds tracked by Wall St. Rank hold ALXN as of Q2 2017.

Princeton Alpha Management reported no remaining Alexion Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
Princeton Alpha Management sold 1,808 Alexion Pharmaceuticals shares in Q2 2017, an estimated $219K.
Princeton Alpha Management first reported a position in Alexion Pharmaceuticals in Q1 2014 and held it in 6 quarters.
Princeton Alpha Management's Alexion Pharmaceuticals position peaked at $3.24M in Q2 2016.
559 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2017.

Based on Princeton Alpha Management's 13F filing for Q2 2017.